Top 5 Drug Type | Count |
---|---|
Small molecule drug | 28 |
Monoclonal antibody | 2 |
Enzyme | 2 |
Chemical drugs | 1 |
Interferons | 1 |
Target |
Mechanism HER2 antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date20 Nov 2024 |
Target |
Mechanism GABAB receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date21 Jul 2020 |
Target |
Mechanism DNA inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date15 Jun 2020 |
Start Date31 Dec 2026 |
Sponsor / Collaborator |
Start Date01 Dec 2025 |
Sponsor / Collaborator |
Start Date30 Sep 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Defibrotide Sodium ( PAI-1 x tPA x vWF ) | Venoocclusive disease More | Approved |
Cytarabine/Daunorubicin Liposomal ( DNA-directed DNA polymerase x Top II ) | Acute Myeloid Leukemia More | Approved |
Asparaginase (Erwinia) ( ASN ) | Adult Lymphoblastic Lymphoma More | Approved |
Solriamfetol Hydrochloride ( 5-HT1A receptor x DAT x NET x TAAR1 ) | Sleep Apnea, Obstructive More | Approved |
Sodium Oxybate/Potassium Oxybate/Calcium Oxybate/Magnesium Oxybate ( GABAB receptor ) | Idiopathic Hypersomnia More | Approved |